Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion.

Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion.

Библиографические подробности
Главные авторы:	Jadersten, M, Pellagatti, A, Forsblom, A, Emanuelsson, E, Merup, M, Samuelsson, J, Wainscoat, J, Boultwood, J, Hellstorm-Lindberg, E
Формат:	Conference item
Опубликовано:	2005

Схожие документы

Lenalidomide up-regulates SPARC and inhibits in vitro growth of the malignant clone in myelodysplastic syndrome patients with 5q deletion.
по: Pellagatti, A, и др.
Опубликовано: (2006)

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
по: Pellagatti, A, и др.
Опубликовано: (2007)

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
по: Jädersten, M, и др.
Опубликовано: (2009)

Del(5q) Myelodysplastic Stem Cells Exhibit Their Clonal Advantage Via Increased Adhesion to the Microenvironment
по: Scharenberg, C, и др.
Опубликовано: (2011)

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression
по: Martin Jädersten, и др.
Опубликовано: (2009-12-01)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome.
по: Pellagatti, A, и др.
Опубликовано: (2011)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome
по: Pellagatti, A, и др.
Опубликовано: (2011)

Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion
по: Martin Jädersten
Опубликовано: (2010-03-01)

Gene expression profiling of day 7 erythroblasts from RARS before and after treatment with G-CSF
по: Nikpour, M, и др.
Опубликовано: (2007)

Gene expression profiling in the myelodysplastic syndromes.
по: Pellagatti, A, и др.
Опубликовано: (2005)

Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
по: Raza Azra, и др.
Опубликовано: (2012-04-01)

Hematological features of patients with myelodysplastic syndromes associated with a chromosome 5q deletion.
по: Lewis, S, и др.
Опубликовано: (1995)

Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells
по: Pellagatti, A, и др.
Опубликовано: (2009)

Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion
по: Maria Ximeri, и др.
Опубликовано: (2010-03-01)

The impact of spliceosome mutations in MDS
по: Jacqueline Boultwood, и др.
Опубликовано: (2019-06-01)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
по: Pellagatti, A, и др.
Опубликовано: (2010)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
по: Pellagatti, A, и др.
Опубликовано: (2010)

5q- syndrome.
по: Boultwood, J, и др.
Опубликовано: (2012)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
по: Pellagatti, A, и др.
Опубликовано: (2010)

Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.
по: Pellagatti, A, и др.
Опубликовано: (2010)

Clonality in the myelodysplastic syndromes.
по: Boultwood, J, и др.
Опубликовано: (2001)

TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.
по: Caceres, G, и др.
Опубликовано: (2013)

Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide
по: Gudrun Göhring, и др.
Опубликовано: (2011-02-01)

The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes.
по: Nilsson, L, и др.
Опубликовано: (2007)

Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)—Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q)
по: Axel Rüfer, и др.
Опубликовано: (2022-07-01)

Molecular pathogenesis of the myelodysplastic syndromes
по: Boultwood, J, и др.
Опубликовано: (1999)

Unusual clonal evolution involving 5q in a case of myelodysplastic syndrome with deletion 5q 31 treated with lenalidomide
по: Virginie Eclache, и др.
Опубликовано: (2008-02-01)

Gene expression profiling in 5q-syndrome and myelodysplastic syndromes.
по: Pellagatti, A, и др.
Опубликовано: (2003)

Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes.
по: Pellagatti, A, и др.
Опубликовано: (2009)

GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome (MDS)
по: Botezatu, L, и др.
Опубликовано: (2016)

Durable Hematological and Major Cytogenetic Response in a Patient with Isolated 20q Deletion Myelodysplastic Syndrome Treated with Lenalidomide
по: Bagi Jana, и др.
Опубликовано: (2014-01-01)

Expression profiling of CD34+cells in patients with myelodysplastic syndromes with and without a del(5q)
по: Pellagatti, A, и др.
Опубликовано: (2005)

Haploinsufficiency of ribosomal proteins and p53 activation in anemia: Diamond-Blackfan anemia and the 5q- syndrome.
по: Boultwood, J, и др.
Опубликовано: (2012)

Telomere length in myelodysplastic syndromes.
по: Boultwood, J, и др.
Опубликовано: (1995)

Haploinsufficiency of RPS14 and Deregulation of Ribosomal- and Translation-Related Genes in MDS Patients with Del(5q)
по: Pellagati, A, и др.
Опубликовано: (2008)

Advances in the 5q- syndrome.
по: Boultwood, J, и др.
Опубликовано: (2010)

Expression profiling of CD34+cells in patients with myelodysplastic syndromes with and without a del(5q).
по: Pellagatti, A, и др.
Опубликовано: (2004)

The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34+ progenitor cells
по: Brigitte Mohr, и др.
Опубликовано: (2009-03-01)

PB2169: LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE COMBINATION THERAPY IN CONCOMITANT MYELODYSPLASTIC SYNDROME WITH ISOLATED 5Q DELETION AND MULTIPLE MYELOMA
по: Yu Han Koh, и др.
Опубликовано: (2023-08-01)

PP2A: The Achilles Heal in MDS with 5q Deletion
по: David eSallman, и др.
Опубликовано: (2014-09-01)